BCL2L1 and kidney injury: For instance, PARP inhibitors have been demonstrated to preserve ATP levels, beneficially influence antioxidant status, and normalize the mitochondrial protective protein Bcl-x levels following chemotherapy-induced kidney injury [29,30].